1 Rubin MN, "What to do with wake-up stroke" 5 : 161-172, 2015
2 Ishrat T, "Vascular protection to increase the safety of tissue plasminogen activator for stroke" 18 : 3677-3684, 2012
3 Keep RF, "Vascular disruption and blood-brain barrier dysfunction in intracerebral hemorrhage" 11 : 18-, 2014
4 Amaro S, "Uric acid therapy prevents early ischemic stroke progression: a tertiary analysis of the URICO-ICTUS trial (efficacy study of combined treatment with uric acid and r-tPA in acute ischemic stroke)" 47 : 2874-2876, 2016
5 Hacke W, "Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke" 359 : 1317-1329, 2008
6 Fu H, "Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia" 29 : 2210-2219, 2011
7 Ballabh P, "The blood–brain barrier: an overview: structure, regulation, and clinical implications" 16 : 1-13, 2004
8 Korninger C, "Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro" 46 : 561-565, 1981
9 Suzuki Y, "Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice" 5 : 1732-1739, 2007
10 Albers GW, "Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies" 42 : 2645-2650, 2011
1 Rubin MN, "What to do with wake-up stroke" 5 : 161-172, 2015
2 Ishrat T, "Vascular protection to increase the safety of tissue plasminogen activator for stroke" 18 : 3677-3684, 2012
3 Keep RF, "Vascular disruption and blood-brain barrier dysfunction in intracerebral hemorrhage" 11 : 18-, 2014
4 Amaro S, "Uric acid therapy prevents early ischemic stroke progression: a tertiary analysis of the URICO-ICTUS trial (efficacy study of combined treatment with uric acid and r-tPA in acute ischemic stroke)" 47 : 2874-2876, 2016
5 Hacke W, "Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke" 359 : 1317-1329, 2008
6 Fu H, "Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia" 29 : 2210-2219, 2011
7 Ballabh P, "The blood–brain barrier: an overview: structure, regulation, and clinical implications" 16 : 1-13, 2004
8 Korninger C, "Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro" 46 : 561-565, 1981
9 Suzuki Y, "Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice" 5 : 1732-1739, 2007
10 Albers GW, "Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies" 42 : 2645-2650, 2011
11 Whiteley WN, "Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis" 15 : 925-933, 2016
12 Blacker DJ, "Reducing haemorrhagic transformation after thrombolysis for stroke: a strategy utilising minocycline" 2013 : 362961-, 2013
13 Ehrenreich H, "Recombinant human erythropoietin in the treatment of acute ischemic stroke" 40 : e647-e656, 2009
14 Lapchak PA, "RIGOR guidelines: escalating STAIR and STEPS for effective translational research" 4 : 279-285, 2013
15 Toni D, "Progressing neurological deficit secondary to acute ischemic stroke. A study on predictability, pathogenesis, and prognosis" 52 : 670-675, 1995
16 Won S, "Progesterone attenuates hemorrhagic transformation after delayed tPA treatment in an experimental model of stroke in rats: involvement of the VEGF-MMP pathway" 34 : 72-80, 2014
17 Bentley P, "Prediction of stroke thrombolysis outcome using CT brain machine learning" 4 : 635-640, 2014
18 Ishiguro M, "Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA" 5 : e15178-, 2010
19 Minnerup J, "Outcome after thrombectomy and intravenous thrombolysis in patients with acute ischemic stroke: a prospective observational study" 47 : 1584-1592, 2016
20 Greenberg DA, "Neurogenesis and stroke" 6 : 321-325, 2007
21 dela Peña I, "Neural Stem Cells in Health and Disease" World Scientific Publishing Co. 371-408, 2015
22 Fylaktakidou KC, "Natural and synthetic coumarin deriv58atives with anti-inflammatory/antioxidant activities" 30 : 3813-3833, 2004
23 Fagan SC, "Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study" 41 : 2283-2287, 2010
24 Wang X, "Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke" 35 : 2726-2730, 2004
25 Ding Q, "Matrix metalloproteinases modulated by protein kinase Cepsilon mediate resistin-induced migration of human coronary artery smooth muscle cells" 53 : 1044-1051, 2011
26 Switzer JA, "Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke" 42 : 2633-2635, 2011
27 Jiang Y, "Low dose tPA plus annexin A2 combination attenuates tPA delayed treatment-associated hemorrhage and improves recovery in rat embolic focal stroke" 602 : 73-78, 2015
28 NINDS rt-PA Stroke Study Group, "Intracerebral hemorrhage after intravenous tPA therapy for ischemic stroke" 28 : 2109-2118, 1997
29 Zuo W, "IMM-H004 prevents toxicity induced by delayed treatment of tPA in a rat model of focal cerebral ischemia involving PKA-and PI3K-dependent Akt activation" 39 : 2107-2118, 2014
30 Koto T, "Hypoxia disrupts the barrier function of neural blood vessels through changes in the expression of claudin-5 in endothelial cells" 170 : 1389-1397, 2007
31 Haelewyn B, "Human recombinant tissue-plasminogen activator (alteplase): why not use the ‘human’ dose for stroke studies in rats?" 30 : 900-903, 2010
32 Lapchak PA, "Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment" 2 : 38-43, 2002
33 Wang W, "Hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke: mechanisms, models, and biomarkers" 52 : 1572-, 2015
34 Jickling GC, "Hemorrhagic transformation after ischemic stroke in animals and humans" 34 : 185-199, 2014
35 Go AS, "Heart disease and stroke statistics—2014 update: a report from the American Heart Association" 129 : e28-e292, 2014
36 Adams HP Jr, "Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association" 34 : 1056-1083, 2003
37 dela Peña IC, "Granulocyte colony-stimulating factor attenuates delayed tPA-induced hemorrhagic transformation in ischemic stroke rats by enhancing angiogenesis and vasculogenesis" 35 : 338-346, 2015
38 Hao JL, "Galardin inhibits collagen degradation by rabbit keratocytes by inhibiting the activation of pro-matrix metalloproteinases" 68 : 565-572, 1999
39 Murata Y, "Extension of the thrombolytic time window with minocycline in experimental stroke" 39 : 3372-3377, 2008
40 Henninger N, "Extending the time window for endovascular and pharmacological reperfusion" 7 : 284-293, 2016
41 Albers GW, "Expanding the window for thrombolytic therapy in acute stroke. The potential role of acute MRI for patient selection" 30 : 2230-2237, 1999
42 Huang Z, "Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine" 16 : 981-987, 1996
43 Shibuya M, "Effect of AT877 on cerebral vasospasm after aneurismal subarachnoid hemorrhage" 76 : 571-577, 1992
44 Culp WC, "Dodecafluoropentane emulsion extends window for tPA therapy in a rabbit stroke model" 52 : 979-984, 2015
45 Machado LS, "Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke" 7 : 56-, 2006
46 Matsumoto M, "Cilostazol in secondary prevention of stroke: impact of the cilostazol stroke prevention study" 6 : 33-40, 2005
47 Ishrat T, "Candesartan reduces the hemorrhage associated with delayed tissue plasminogen activator treatment in rat embolic stroke" 38 : 2668-2677, 2013
48 Tan Z, "Bryostatin improves survival and reduces ischemic brain injury in aged rats after acute ischemic stroke" 44 : 3490-3497, 2013
49 Tan Z, "Bryostatin extends tPA time window to 6 h following middle cerebral artery occlusion in aged female rats" 764 : 404-412, 2015
50 Borlongan CV, "Bone marrow stem cell mobilization in stroke: a ‘bonehead’ may be good after all!" 25 : 1674-1686, 2011
51 Sobrino T, "Association of growth factors with arterial recanalization and clinical outcome in patients with ischemic stroke treated with tPA" 8 : 1567-1574, 2010
52 Allahtavakoli M, "Ascorbic acid reduces the adverse effects of delayed administration of tissue plasminogen activator in a rat stroke model" 117 : 335-339, 2015
53 Mayne M, "Antisense oligodeoxynucleotide inhibition of tumor necrosis factor-alpha expression is neuroprotective after intracerebral hemorrhage" 32 : 240-248, 2001
54 Ullegaddi R, "Antioxidant supplementation with or without B-group vitamins after acute ischemic stroke: a randomized controlled trial" 30 : 108-114, 2006
55 Hartung T, "Anti-inflammatory effects of granulocyte colony-stimulating factor" 5 : 221-225, 1998
56 Zhu H, "Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke" 30 : 1137-1146, 2010
57 Meenakshisundaram T, "Activated protein C promotes neovascularization and neuro-genesis in post-ischemic brain via protease activated receptor 1" 28 : 12788-12797, 2008
58 Parsons M, "A randomized trial of tenecteplase versus alteplase for acute ischemic stroke" 366 : 1099-1107, 2012
59 Berkhemer OA, "A randomized trial of intraarterial treatment for acute ischemic stroke" 372 : 1009-1018, 2014
60 Mishiro K, "A broad-spectrum matrix metalloproteinase inhibitor prevents hemorrhagic complications induced by tissue plasminogen activator in mice" 205 : 39-48, 2012
61 Ishiguro M, "A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator" 220 : 302-312, 2012